MedTrace Logo

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

NCT03058822 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2017-12-20

No results posted yet for this study

Summary

A Phase 1, relative bioavailability study of BMS-931699 from prefilled syringe compared to drug in vial

Conditions

  • Healthy

Interventions

DRUG

BMS-931699

BMS-931699 single subcutaneous dose on Day 1

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-25
Primary Completion
2017-03-30
Completion
2017-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03058822 on ClinicalTrials.gov